trametinib,dabrafenib
novartis
['trametinib', 'rectal', 'colorectal', 'dabrafenib']
 figure clearly shows tissue agnostic activity of dabrafenib+ trametinib across all braf v600 + cancers ! #precisionmedicine
one exception is colorectal cancer - which needs egfr inhibition in addition to braf inhibition #aacr23 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.